638 F.3d 401 (2nd Cir. 2011), 10-4630-cv, Cacchillo v. Insmed, Inc.
|Citation:||638 F.3d 401|
|Opinion Judge:||WESLEY, Circuit Judge:|
|Party Name:||Angeline CACCHILLO, Plaintiff-Appellant, v. INSMED, INC., Defendant-Appellee.|
|Attorney:||Kevin A. Luibrand, Albany, NY, for Plaintiff-Appellant. Robert P. Charrow (Laura Metcoff Klaus, Cynthia E. Neidl, on the brief), Greenberg Traurig LLP, Washington, D.C., for Defendant-Appellee.|
|Judge Panel:||Before: WESLEY, CHIN, and LOHIER, JR., Circuit Judges.|
|Case Date:||March 23, 2011|
|Court:||United States Courts of Appeals, Court of Appeals for the Second Circuit|
Argued: March 15, 2011.
Plaintiff-Appellant Angeline Cacchillo appeals from an October 22, 2010 order of the United States District Court for the Northern District of New York (McAvoy, J. ) denying Cacchillo's motion for a preliminary injunction for lack of standing. For the reasons stated below, we find that Cacchillo has standing to pursue a preliminary injunction and that her claim, contrary to Defendant-Appellee Insmed Inc.'s (" Insmed" ) suggestion, is ripe for review. We nevertheless AFFIRM because Cacchillo has not met her burden to obtain the preliminary injunction because she has not shown the requisite likelihood of success on the merits.
Cacchillo suffers from Type 1 Myotonic Muscular Dystrophy (" MMD1" ). From February 2008 to August 2008, Cacchillo took Insmed's drug IPLEX while participating in a clinical trial for MMD1 patients. Cacchillo felt her condition greatly improved while on IPLEX and brought this action in part because she hopes to resume taking IPLEX.
The Food and Drug Administration (" FDA" ) has not approved IPLEX for general use. As a result, Cacchillo cannot resume IPLEX treatment unless she receives a special authorization— known as a " compassionate use" exception— from the FDA. Cacchillo contends that before she may file a compassionate use application, Insmed— as the manufacturer of IPLEX— must provide her with a form to be forwarded to the FDA stating that Insmed will provide Cacchillo with IPLEX in the event her application is approved. Insmed has refused to participate in this process. Further complicating matters, IPLEX is no longer produced, only limited stores of IPLEX remain and, according to Insmed, all remaining IPLEX has been committed to patients with amyotrophic lateral sclerosis (" ALS" ).
Cacchillo asserts that Insmed agreed to support her FDA compassionate use application and is now in breach of that agreement. Cacchillo commenced this action asserting claims pursuant to 42 U.S.C. § 1983 and New York State common law challenging Insmed's refusal to support her application. Cacchillo moved for a preliminary injunction requiring Insmed to:
(1) " provide to Angeline Cacchillo a written statement directed to the United States Food and Drug Administration ... in a form customary for such submissions supporting the ‘ compassionate use’ of ... IPLEX for Angeline Cacchillo, stating that Insmed, Inc. will, without reservation, provide Angeline Cacchillo the medication IPLEX at cost upon the granting of her compassionate use application by the FDA; " and (2) " directing Insmed, Inc., in the event that Angeline Cacchillo's application is granted by the FDA, to provide Angeline Cacchillo IPLEX...."
Insmed opposed the motion, arguing, among other things, that Cacchillo lacked standing to pursue a preliminary injunction because her injury cannot be redressed when the remaining stores of IPLEX have already been committed to ALS patients. The district court agreed and denied Cacchillo's motion.
On appeal, Insmed contends that Cacchillo cannot establish either standing or...
To continue readingFREE SIGN UP